Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-4471

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-4471). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4471 3

Label for Losartan Potassium 50 mg film-coated tablets by NuCare Pharmaceuticals, Inc., with NDC 68071-4471-3. The label indicates a package size of 30 tablets, Rx only, and includes manufacturer information for Hetero Labs Limited, India. It also contains barcodes, lot and expiration placeholders, and storage instructions to keep at controlled temperature (68-77°F).*

FDA Label Image

Losartanaddress1 (Losartanaddress1)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line chart comparing the percentage of patients with a primary endpoint over a 60-month study period for two drugs: Losartan Potassium and Atenolol. The X-axis represents study months, and the Y-axis shows the percentage of patients. The chart includes an adjusted risk reduction value of 13% with a p-value of 0.021 favoring Losartan Potassium.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line chart comparing the percentage of patients with fatal or non-fatal stroke over 66 study months between Losartan potassium and Atenolol. Losartan potassium shows a lower percentage of such patients over time, with an indicated adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol event rates in various subgroups. The chart presents hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) outcomes by age, gender, race, ISH, diabetes, and history of CVD.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan Potassium versus placebo. The graph shows two curves representing Losartan Potassium and placebo, with an annotation indicating a risk reduction of 16.1% and a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium showing its molecular components, including aromatic rings, chlorine, hydroxyl groups, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.